Abstract Expansion of the FRAXE CCG repeat to a full mutation is associated with methylation and transcriptional silencing of the FMR2 gene, and as a consequence, mild-toborderline mental retardation. FMR2 is a member of a family of four proteins, AF4, LAF4, FMR2, and AF5q31. The proteins associated with this family localize to the cell nucleus. Various regions of FMR2, and each of the other members of the protein family, were cloned and analyzed for transcription activation in yeast and mammalian cells. In both yeast and mammalian cells, FMR2 showed strong transcription activation. AF4 activation potential was severalfold lower. Interestingly, isoforms of both FMR2 and LAF4 lacking exon 3 activated transcription better than the larger isoforms containing exon 3. Compared with the other members of the family, activation by FMR2 was the strongest. Our results show that FMR2 is a potent transcription activator and that its function is conserved. Elucidation of the function of the FMR2 protein as a transcription activator may place FMR2 within the molecular signalling pathways involved in nonspecific X-linked mental retardation (MRX).
Introduction
FMR2, the gene associated with the FRAXE fragile site, was the first gene for a nonspecific familial X-linked mental retardation (XLMR) to be identified (Gecz et al. 1996; Gu et al. 1996) . The prevalence of FRAXE (mental retardation; MIM no. 309548) is estimated to be 1/50,000 to 1/100,000 live births (Mulley et al. 1995; Brown 1996) and it is the most prevalent form of nonspecific XLMR so far identified. FRAXE MR is a mild-to-borderline mental retardation (50 Ͻ IQ Ͻ 85) which manifests as learning difficulties and speech and behavioral problems. Several FRAXE full mutation males have been described with IQ within the normal range (Mulley et al. 1995; Murgia et al. 1996; Gecz et al. 1997b; Lo Nigro et al. 2000 ; for review, see Gecz 2000) .
The FMR2 gene is transcribed as a major 8.75-kb transcript (Gecz et al. 1997a) . Shorter (Ox19; ~1.5 kb; Chakrabarti et al. 1996) and longer (13.7kb; Gecz and Mulley 1999 ) specific isoforms were observed, the latter expressed predominantly in fetal brain. Additionally, alternative splicing of at least 5 of 20 internal exons was detected (Gecz et al. 1997a) . The largest open reading frame of 3933bp is translated into a 1311 amino acid hydrophilic protein which is localized to the cell nucleus (Gecz et al. 1997a) . Database searches have shown that the FMR2 protein is a member of a family of proteins including AF4 (Morrissey et al. 1993) , LAF4 (Ma and Staudt 1996) , and the recently characterized chromosome 5 gene AF5q31 (Taki et al. 1999) . Paralogous members of this AF4/LAF4/ FMR2/AF5q31 gene family show several similarities: size of transcript(s) at about 1.5, 8.0, and 13kb; alternative splicing and gene structure conservation (Gecz et al. 1997a; Nilson et al. 1997) ; protein size of ~1300 amino acids; and nuclear localization of the proteins (Ma and Staudt 1996; Gecz et al. 1997a) . AF4 was identified because of its involvement in a t(4;11) translocation, resulting in a fusion with the ALL1 (MLL) gene, causing acute lymphoblastic leukemia (ALL) (Prasad et al. 1995) . LAF4 (Ma and Staudt 1996) , identified from Raji Burkitt's lymphoma cells, is thought to have a role in lymphoid development. Preliminary studies on AF4 (Prasad et al. 1995) and LAF4 (Ma and Staudt 1996) show that these proteins have the potential to activate transcription of a reporter gene in an in-vivo transcription activation assay.
The normal function of the FMR2 protein is unknown. In the present study, we analyzed the transcription activa-tion potential of FMR2 and compared it with the other members of the gene family in yeast and mammalian cells. Our results show that, in this system, FMR2, AF4, and LAF4 are potent transcription activators. Interestingly, an alternative splicing product of FMR2 and LAF4 lacking exon 3 led to elevated transcription activation of the reporter gene in both yeast and mammalian cells.
Materials and methods

Plasmids
Effector plasmids were either pGBT9 or pM (Clontech, Palo Alto, CA, USA). These two vectors contained a GAL4 DNA binding domain (BD; amino acids 1-147), in pGBT9 flanked by the yeast ADH1 promoter and ADH1 transcription termination signal, and in pM flanked by the simian virus 40 (SV40) early promoter and polyA transcription termination signal. The pG5CAT (Clontech) reporter vector was used in cotransfections with pM into mammalian cells. pG5CAT contained the chloramphenicol acetyltransferase (CAT ) gene downstream of 5 consensus GAL4 upstream activating sequences (UAS G17-mer(ϫ5) ) and an adenovirus E1b minimal promoter. The -galactosidaseexpressing plasmid (pSV-) was obtained from Promega (Madison, WI, USA) and used to normalize transfection efficiencies between experiments. All constructs were examined for expression of the GAL4 chimeric proteins by transfection into yeast or HeLa cells, and subsequent assays for transcription activation were carried out usinggalactosidase and CAT assays.
Design and preparation of expression constructs
Expression vectors for fusions between FMR2, LAF4, AF4, AF5q31, or ALL1 and the GAL4 DNA-BD were made by cloning reverse transcription (RT)-polymerase chain reaction (PCR) amplified fragments of the corresponding gene into the multiple cloning site of either the pM or pGBT9 vectors. mRNA was isolated using Trizol reagent (GIBCO BRL, Grand Island, NY, USA) according to the manufacturer's protocol. Approximately 500 ng of purified mRNA was random primed for first-strand cDNA synthesis, using SuperScript II RNAse H -reverse transcriptase (GIBCO BRL). Reverse transcription was carried out for 1 h at 42°C in a thermal cycler (Hybaid, Ashford, Middlesex, UK). Negative controls, containing no reverse transcriptase, were run at the same time. Fragments were amplified from fetal brain (Gecz et al. 1997a ) cDNA by PCR, using primers designed to contain a restriction enzyme site (see Table 1 (Fig. 1a,b) . After amplification, the PCR products were digested with restriction enzymes and cloned into the pM or pGBT9 vectors. An amount of 5-300 ng of the digested PCR product and 50 ng of the vector were ligated at 4°C overnight and transformed into XL1 Blue competent cells. The following day, positive clones were detected via colony PCR. The plasmid DNA was prepared using a QIAGEN Plasmid Mini Kit (Bothell, WA, USA).
Positive constructs were sequenced using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (ABI, Foster City, CA, USA), to confirm that constructs had the correct insert and that the insert was in the correct reading frame. Yeast cell transformations and -galactosidase assays An amount of 0.1 µg of each experimental plasmid was transformed into competent Saccharomyces cerevisiae Y187 reporter strain, using the LiAc method protocol described in the TransAct Assay Kit (Clontech). S. cerevisiae Y187 contains an integrated lacZ reporter construct which is regulated by a wild-type GAL1 promoter. The GAL4 DNA binding domain has a high affinity for the GAL1 promoter. The recombinant pGBT9 derivative is transformed into Y187 where the fusion protein is expressed and targeted to the nucleus. Colonies containing the correct plasmid clone were detected via colony PCR, and then used to assay for transcription activation. If the protein of interest acted as an activator, then transcription of the lacZ gene would be initiated. This was detected by blue/white screening forgalactosidase activity, using a colony lift filter assay, and further quantified using -galactosidase assays of liquid cultures (Clontech). For each transfection, the following controls were used: (1) pCL1 as a strong positive control, (2) pGBT9 ϩ HA as a weak control, (3) the ALL1/pGBT9 construct containing the ALL1 activation domain, and (4) wild-type pM vector as a negative control. Transformations with all constructs were repeated three times.
Mammalian cell transfection experiments
A total of 5 ϫ 10 5 HeLa cells in 100-mm culture dishes were transfected for 5 h, using 14µg/ml of LipofectAMINE Reagent (GIBCO BRL) according to the manufacturer's specifications, with 2 µg of each of the pM derivatives, 2 µg of the pG5CAT reporter plasmid, and 0.4 µg of the pSVplasmid, expressing -galactosidase and used as an internal control to normalize transfection efficiency. Cellular extracts were prepared 48 h post-transfection. CAT assays were performed as described in the Boehringer Mannheim CAT enzyme-linked immunosorbent assay (ELISA) Kit. The amount of extract used in the CAT assay was adjusted to 50 µg/µl, based on the total amount of protein for each extract. Results of all CAT assays were normalized according to the -galactosidase values.
For each transfection, the following controls were used: (1) the pM3-VP16 as a strong positive control containing the activation domain of the herpes virus, (2) the ALL1/pM construct encoding the ALL1 activation domain, and (3) wild-type pM vector as a negative control of transfection. Transfections with all constructs were repeated at least three times.
RT-PCR analysis
After transfection, cells were harvested and RNA was isolated from approximately 10 4 cells, using Trizol reagent (GIBCO BRL). To remove trace amounts of plasmid or genomic DNA, RNA was treated with 2U RNase-free DNase 1 for 30 min at 37°C. DNase was removed from the sample by incubation with a DNase inactivation reagent (Ambion, Austin, TX, USA) for 2 min at room temperature. An amount of 1 µg of purified total RNA was random primed for first-strand cDNA synthesis as described above. PCR amplifications using a GAL4-DNA-BD-specific forward primer (4.4: 5Ј-GACAGCATAGAATAAGTGCG AC-3Ј) and exon 2 FMR2 gene-specific reverse primer (E2R1: 5Ј-CGTCTTCTTGCTGGACTTCTTG-3Ј) were carried out to ensure that recombinant plasmid-specific transcripts were produced. Standard conditions for PCR were 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C for 10 cycles, then 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C for 25 cycles, using the conditions described above. PCR products were analyzed on a 2% agarose gel.
Results
Definition of a minimal transactivation domain
Previous studies on AF4 and LAF4, two members of the AF4/LAF4/FMR2/AF5q31 gene family (Prasad et al. 1995; Ma and Staudt 1996) indicated that these proteins may act as transcription activators. Initially, based on overlapping regions shown to activate transcription, small constructs containing the putative minimal activation domain were designed from all four members of the family: AF4 (AA464-523); LAF4 (AA426-484), FMR2 (AA481-541), and AF5q31 (Fig. 1a,b) . However, assays using these "minimal constructs" in both yeast and mammalian cells showed no activation (see below). Subsequently, larger constructs, spanning most of the NH 2 terminus of the proteins, were designed, some of them identical to those previously tested (Prasad et al. 1995; Ma and Staudt 1996) . Based on the AF4 and LAF4 activating regions, corresponding FMR2 protein constructs were designed. These comprised mostly the NH 2 terminus of the protein where extensive alternative splicing was observed (Gecz et al. 1997a ). We did not prepare and analyze all possible FMR2 protein isoforms, focussing on the isoform missing the large exon 3 (~290 amino acids) and exon 5. By DNA sequencing we confirmed that the smaller isoform corresponded to FMR2 lacking exon 3, exon 5, and exon 7A (Gecz et al. 1997a ). Our results showed that corresponding regions were also alternatively spliced in LAF4 (results not shown); thus, a construct lacking these regions in LAF4 was prepared as well. A schematic representation of all constructs used in the study is shown in Fig. 1a . The corresponding amino acid sequence is shown in Fig. 1b .
Transcription activation assays in S. cerevisiae Y187 All putative activation domains were initially tested in S. cerevisiae, using the -galactosidase colony lift assay, and then using liquid o-nitrophenyl -D-galactopyranoside (ONPG) assays. For all "minimal constructs" no activation was detected using either the colony lift assay (data not shown) or the more sensitive liquid ONPG assay (Fig. 2) . Subsequently, the larger constructs were tested. Both FMR2 2-L and FMR2 2-S augmented transcription of a reporter gene construct significantly, indicated by a rapid and strong color substrate reaction in both colony lift (data not shown) and liquid ONPG assays (Fig. 2) . Interestingly, the shorter FMR2 2-S isoform, lacking exons 3, 5, and 7A, showed a much higher activation (40% higher, Fig. 2 ) than the larger exon 3-containing isoform FMR2 2-L . The level of activation of FMR2 2-S was higher than that of the control ALL1 construct (twofold), but less than that of the pCL1 strong positive control (twofold; data not shown). The large FMR2 2-L construct activated at the level of the positive control ALL1 (Fig. 2) . The LAF4 2-L and LAF4 2-S constructs with and without exon 3 showed potent activation, with the smaller (LAF4 2-S ) isoform similarly showing higher (~tenfold) levels of transcription activation than the larger (LAF4 2-L ; Fig. 2) . AF4 was also shown to activate transcription (~tenfold less than ALL1), while AF5q31 did not. However, for this protein, only the AF5q31 minimal domain was tested, as the entire protein sequence was not available. In conclusion, the activation potential among the tested proteins was highest for FMR2.
Transcription activation assays in HeLa cells
All constructs used for transfection experiments were sequenced to confirm the open reading frame and to confirm that no mutations had occurred during the cloning process. Also, an internal control of protein expression ( -galactosidase expression plasmid pSV-, see "Materials and methods") was used in each transfection experiment. In order to confirm the in-vivo transcription from the recombinant pM vector constructs, total RNA was isolated from the transfected cells, DNased (to remove the recombinant plasmid DNA), reverse transcribed, and PCR amplified, using a combination of GAL4-DB-and FMR2-specific primers. An example of this experiment is shown in Fig. 3 .
Results of the HeLa assays (CAT ELISA) are shown in Fig. 4 . All CAT activities were normalized to correct for any differences in transfection efficiency. The FMR2, AF5q31, LAF4, and AF4 "minimal" constructs did not exhibit any significant activation in HeLa cells, concordant with the results observed in yeast cells (Fig. 2) . Both AF4 and LAF4 were seen to significantly augment transcription of the CAT reporter gene (Fig. 4) . Consistent with the results of the yeast assay, the highest level of activation was observed for the short (FMR2 2-S ) isoform. However, in this system, activation by FMR2 2-S was tenfold greater than that by LAF4 2-S , and about 40% higher with respect to the ALL1 control activation domain. analysis of the recombinant GAL4-DB/FMR2 RNA. As shown for the two FMR2 constructs, FMR2 2-L and FMR2 2-S , the recombinant RNA is produced from the transfected constructs. To control the quality of RNA, esterase D primers were used. The numbers above the lanes correspond to the oligonucleotides used (see Material and methods); ϩ and Ϫ indicate lanes with and without the presence of reverse transcriptase in the cDNA synthesis reaction, as a marker, pUC/HpaII was used Tissue specificity of FMR2 exon 3 alternative splicing It has been shown previously (Gecz et al. 1997a ) that the 5Ј end of FMR2 is alternatively spliced. To study the alternative splicing of the larger exon 3, fetal and infant brain mRNA was analyzed. Although the most abundant is the exon 3-containing isoform (FMR2 2-L ), a significant difference in abundance of the exon 3-missing isoform (FMR2 2-S ) was detected (Fig. 5) . Consistently, the level of the exon 3-missing isoform is higher in infant brain than in fetal brain. However, the overall expression of FMR2 seems to be upregulated in infant brain.
Further analysis of the FMR2 protein
To gain insight into the basis for different transcription activation potentials of the four proteins studied, corresponding paralogous regions (exon 1-exon 10) of these proteins were examined (Fig. 1b) . Amino acid sequence comparison showed that conservation across this region (Fig. 6 ) is in the range of 27% (FMR2 versus AF5q31) to 38.9% (FMR2 versus LAF4). After removal of the sequence of the large exon 3 (287 amino acids for the FMR2 protein), the overall conservation was slightly higher (40%-53%; results not shown). We speculated that differences of transcription activation potential observed, at least for the FMR2 and LAF4, might be a consequence of different acidity and, thus, different charge of these proteins. Both the large FMR2 2-L and LAF4 2-L constructs tested have a relatively high negative charge, Ϫ28.29 and Ϫ7.3, respectively. The deduced amino acid sequence of the FMR2 2-L protein shows that it has a primary length of 511 amino acids with an estimated mass of 56.4 kDa and is rich in serine (68 residues; 13.3%) and proline (51 residues; 10.0%) amino acids. The larger LAF4 2-L isoform has a length of 460 amino acids, with an estimated mass of 50.3 kDa and is rich in serine (64 residues; 13.9%) and proline (39 residues; 8.5%) amino acids. Removal of the amino acids of the alternatively spliced exon 3 and exons 5 and 7A results in an increase in the negative charge of LAF4 (Ϫ16.6), AF4 (from Ϫ15.0 to Ϫ23.8), and AF5q31 (from ϩ0.37 to Ϫ15.13) proteins. For FMR2, the negative charge is slightly lower (Ϫ22.29). The amino acid sequence of the FMR2 2-S protein has a primary length of 222 residues with an estimated mass of 25.1 kDa and is rich in serine (28 residues; 12.6%), glutamine (25 residues; 11.3%), and proline (19 residues; 8.6%) amino acids. Lastly, the deduced amino acid sequence of the LAF4 2-S protein shows that it has a primary length of 199 amino acids with an estimated mass of 21.6 kDa and is rich in serine (38 residues; 19.1%), glutamine (22 residues; 11.1%), and proline (18 residues; 9.0%) amino acids. In conclusion, the increase in transcription activation potential of the protein constructs tested in this study (especially FMR2) correlated with the negative charge of that protein.
Discussion
FMR2 belongs to a family of four genes AF4, LAF4, FMR2, and AF5q31. Three of these genes were found to be associated with morbid phenotype; AF4 (Prasad et al. 1995) , AF5q31 (Taki et al. 1999) , and FMR2 (Gecz et al. 1996; Gu et al. 1996) . Two of them, AF4 and AF5q31, were found to be involved in acute lymphoblastic leukemia (ALL), as rearrangement partners of the ALL1 gene. An LAF4-associated phenotype is not yet known; however, based on its expression, it is thought to have a role in lymphoid development (Ma and Staudt 1996) . FMR2 is involved in a mildto-borderline form of nonspecific X-linked mental retardation (Gecz et al. 1997b; Gecz 2000) .
Our aims for this study were: (i) primarily to determine whether FMR2 possessed a transcription activator function; (ii) to test whether this function was conserved; (iii) to assess levels of transcription activation by FMR2 in comparison with that by other members of the gene family; and (iv) to compare this activity with that of other known transcription activators (e.g., ALL1, VP16).
We tested different regions of FMR2 in comparison to the other member proteins for transcription activation in yeast and HeLa cells. Previous studies on both AF4 (Prasad et al. 1995; Morrissey et al. 1997 ) and LAF4 (Ma and Staudt 1996) have shown that these proteins can activate transcription. In our study, we show that FMR2 does efficiently activate the GAL4-E1b GAL1 and CAT reporter in both yeast and HeLa cells, respectively (Figs. 2,4) . Our results also confirm previous studies on LAF4 and AF4 (Prasad et al. 1995; Ma and Staudt 1996) . Regarding the AF5q31 gene, only a partial protein sequence was available until recently (Frestedt et al. 1996; Gecz et al. 1997a) . Taki et al. (1999) cloned and characterized this gene, which they called AF5q31. The AF5q31 gene encodes a 1163-amino acid protein, which is similar to AF4, LAF4, and FMR2. We did not find transcriptional activation for the small AF5q31 construct, but a larger region was not tested. Based on our studies and conservation across the tested regions, we predict that the AF5q31 protein might also act as a transcription activator protein. In conclusion, the members of the AF4/LAF4/FMR2/AF5q31 family of proteins are able to activate transcription in yeast as well as mammalian cells.
Observation of alternative splicing within FMR2 and LAF4 and its role in transcription activation is interesting.
Comparison of fetal and infant brain cDNAs showed that FMR2 isoforms, lacking especially the large exon 3, had different abundance in either tissue. The smaller isoform is relatively more abundant in fetal brain than in infant brain. Smaller isoforms for either FMR2 or LAF4 showed consistently augmented levels of transcription activation. Thus, it would be of great interest to determine the spatial and temporal pattern of transcription of either of the FMR2 2-L FMR2 2-S isoforms. Differential transcription activation due to alternative splicing is not exclusive to FMR2; it has been documented for other proteins, including SMAD2 (Yagi et al. 1999) , BRCA1 (Cui et al. 1998) , and the orphan nuclear receptor CAR (Choi et al. 1997) .
Alternative splicing of transcripts can result in proteins that have lost the ability to bind to a specific target sequence (Choi et al. 1997) or proteins that have increased ability to bind DNA (Yagi et al. 1999) . Alternatively, splicing may lead to removal of an activation region (Cui et al. 1998 ) and subsequent aberrant transcription activation capacity. Our study has shown that removal of the large exon 3 in FMR2 and LAF4 acts to increase transcription activation. Removal of a repressive domain, in a similar mechanism to that of the MH2 domain in SMAD2 allowing the MH1 domain to bind DNA (Yagi et al. 1999) , may also be the case for FMR2. Conversely, physical changes in protein structure may effect activation levels. Travers (1998) discusses the idea that conformational changes in DNA and proteins are important for complex formations between transcription factors. This is interesting in light of our findings that alternative splicing results in varied transcription activation levels. It is also interesting to note that the larger product is more abundant than the smaller isoform. This variation in abundance may act as a regulatory mechanism for controlling transcriptional activation by the FMR2 protein.
The function of transcription activation is to augment the basal levels of transcription of eukaryotic mRNA by RNA polymerase II. Several models for this action have been proposed (Mitchell and Tjian 1989; Triezenberg 1995; Kingston et al. 1996; Ptashne and Gann 1997) . Studies of the herpes simplex VP16 activation domain have shown that activation processes require biochemical interactions between activation region(s) and specific target protein(s) that depend most directly upon hydrophobic residues within helical segments of the activator (Sullivan et al. 1998) . Paralogous regions of the AF4/LAF4/FMR2/AF5q31 family were analyzed in this respect, and these regions could therefore be correlated with their similar activation potential. The LAF4 and AF4 proteins have also been shown to have a nonspecific DNA binding potential (Prasad et al. 1995; Ma and Staudt 1996) . Goodman and Mandel (1998) have suggested that transcription activators do not necessarily bind DNA directly. Rather, these transcription activators may act by modifying chromatin factors that repress gene expression, by linking DNA binding transcription activators to the basal transcription apparatus, or by altering components of the transcriptional machinery through covalent modifications. FMR2 and other members of the family may act by interacting with other proteins of the transcriptional machinery along these lines. The DNA binding capacity of FMR2 has not yet been tested. Computer analysis of FMR2 shows that the protein does not contain a recognized DNA binding domain motif, but does contain a helix-loop-helix dimerization domain signature (ETVELLRYA [1090] [1091] [1092] [1093] [1094] [1095] [1096] [1097] [1098] ), a domain that is known to interact with other proteins to form heterodimers (Dowell et al. 1992) . The role of FMR2 (and the other members of the family) in transcription activation is also supported by the nuclear localization of the corresponding protein (Gecz et al. 1997a) . Interestingly, the dispersed pattern of speckled nuclear localization for some FMR2-GFP constructs (data not shown) is very similar to the localization of other members of the transcription machinery (Jolly et al. 1999; Verschure et al. 1999; Berube et al. 2000) .
Currently, at least eight genes have been identified as being involved in a form of nonspecific X-linked mental retardation: FMR2 (Gecz et al. 1996; Gu et al. 1996) ; GDI1, a Rab GDP-disassociation inhibitor (D'Adamo et al. 1998); OPHN1, a Rho-GTPase-activating protein (Billuart et al. 1998) ; PAK3, a p21-activated kinase (Allen et al. 1998 ); RPS6KA3, a growth factor-induced kinase (Merienne et al. 1999) ; IL1RAPL, an interleukin (IL)-1 receptor accessorylike protein (Carrie et al. 1999) ; TM4SF2, a member of the tetraspanin family of proteins (interaction with 1-integrins; Zemni et al. 2000) ; and ARHGEF6, a guanine nucleotide exchange factor for Rho GTPase (Kutche et al. 2000) . Only FMR2 has not yet been shown to participate in intracellular signalling (Chelly 1999; Gecz 2000; Gecz and Mulley 2000) . Elucidation of a function for FMR2 in the activation of transcription may place FMR2 as one of the downstream effectors of the newly discovered MRX genes. The function of the FMR2 protein can be regulated in a manner similar to that of the CREB transcription factor, via phosphorylation by RSK2 (RPS6KA3; Merienne et al. 1999 ) or yet another kinase. A putative phosphorylation site was identified in FMR2 in the vicinity of the bipartite nuclear localization sequences (J. Gecz; unpublished results). The proposed role of FMR2 in transcription regulation is also attractive from the point of view of the mild nature of the FMR2-associated mental retardation phenotype. Moreover, although the function of FMR2 as a transcription regulator seems to be conserved (yeast activation study results; see above), most probably it is also, at least partially, redundant. This can be supported by the existence of several examples of individuals who do not have any detectable FMR2 product and who are not affected (Lo Nigro et al. 2000; for review, see Gecz 2000) .
FMR2-associated mental retardation is the most prevalent form of nonspecific mental retardation yet characterized (Gecz 2000) . Although our study does not provide comprehensive evidence of FMR2 function, it points toward a pathway and molecular process in which FMR2 may take part. Investigation of proteins that interact with FMR2, and genes in which transcription is regulated by FMR2, will be the next step in the elucidation of its function and its role in mental retardation.
